Nyxoah Archives | Be Korea-savvy
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium, Apr. 11 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD [...]

Information on the Total Number of Voting Rights and Shares (Nyxoah)

Information on the Total Number of Voting Rights and Shares (Nyxoah)

Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET (Korea Bizwire) – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new [...]

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation First medical device company to become a corporate champion at the ENTerprise Circle level Mont-Saint-Guibert, Belgium – March 25, 2024, 7:05am CET / 2:05am ET (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a [...]

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints

Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002) Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (p<0.001) Median 12-month AHI reduction of 70.8% Mont-Saint-Guibert, Belgium, Mar. 19 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the [...]

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results Expect to report DREAM U.S. pivotal study efficacy and safety data by early April Achieved record quarterly sales of €1.8 million Mont-Saint-Guibert, Belgium, Mar. 5 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the [...]

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the [...]

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Mont-Saint-Guibert, Belgium, Feb. 15 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, [...]

Nyxoah Announces 2024 Strategic Priorities

Nyxoah Announces 2024 Strategic Priorities

Mont-Saint-Guibert, Belgium, Jan. 17 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024.             2024 Strategic Priorities Complete patient follow [...]

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Mont-Saint-Guibert, Belgium, Jan. 9 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023.    Preliminary, Unaudited Fourth [...]

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73% Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET (Korea Bizwire) – Nyxoah SA (Euronext [...]